前列腺特异性膜抗原(PSMA)PET显像冷 kit:68Ga-三(羟基吡啶酮)-PSMA PET/CT 在前列腺癌患者中的1期研究
这项1期研究评估了68Ga-THP-PSMA的安全性与生物分布:A组8例拟行前列腺切除术的前列腺癌患者(Gleason评分7-10,平均PSA 7.8 μg/L)接受PET/CT,B组6例68Ga-HBED-PSMA-11阳性患者进行对比扫描。未发生不良事件;A组6/8例前列腺局灶摄取与PSMA免疫组化3+染色对应,平均有效剂量2.07E-02 mSv/MBq;B组68Ga-THP-PSMA的生理本底摄取低于68Ga-HBED-PSMA-11(腮腺平均SUVmax 3.6 vs 19.2,肝2.7 vs 6.3,脾2.7 vs 10.5,P均<0.001)。
要点
- 68Ga-THP-PSMA未发生不良事件,平均有效剂量2.07E-02 mSv/MBq。
- A组6/8例前列腺局灶摄取(2 h平均SUVmax 5.1,范围2.4-9.2)与PSMA免疫组化3+染色对应。
- B组68Ga-THP-PSMA腮腺、肝、脾平均SUVmax均低于68Ga-HBED-PSMA-11(P<0.001)。
核心结论
- 68Ga-THP-PSMA是安全的,并具有适合临床显像的良好生物分布。
- 前列腺内观察到的局灶摄取在组织病理学上定位于表达PSMA的恶性组织。
- 68Ga-THP-PSMA PET也可显示转移性PSMA亲和病灶。
- 采用良好生产规范冷 kit 的单步生产可能有助于快速推广。
研究设计与样本
- 1期研究,A组8例经证实的前列腺癌患者,计划行前列腺切除术,Gleason评分7-10,平均前列腺特异性抗原7.8 μg/L(范围5.4-10.6 μg/L)。
- 所有患者接受68Ga-THP-PSMA PET/CT后行前列腺切除术(7例加盆腔淋巴结清扫)。
- 采用OLINDA/EXM进行多时间点PET显像的剂量学分析。
- B组6例68Ga-HBED-PSMA-11 PET/CT阳性患者,接受对比性68Ga-THP-PSMA扫描。
- 所有患者监测不良事件。
主要发现
- 未发生不良事件。
- A组8例中6例前列腺局灶摄取(2 h平均SUVmax 5.1,范围2.4-9.2),前列腺切除标本PSMA免疫组化呈3+染色。
- 2例68Ga-THP-PSMA扫描阴性者仅见1+/2+染色。
- 平均有效剂量为2.07E-02 mSv/MBq。
- B组68Ga-THP-PSMA的生理本底摄取低于68Ga-HBED-PSMA-11:腮腺平均SUVmax 3.6 vs 19.2,肝2.7 vs 6.3,脾2.7 vs 10.5,P均<0.001。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
68Ga-labeled urea-based inhibitors of the prostate-specific membrane antigen (PSMA), such as 68Ga-labeled N,N'-bis(2-hydroxybenzyl)ethylenediamine-N,N'-diacetic acid (HBED)-PSMA-11, are promising small molecules for targeting prostate cancer. A new radiopharmaceutical, 68Ga-labeled tris(hydroxypyridinone) (THP)-PSMA, has a simplified design for single-step kit-based radiolabeling. It features the THP ligand, which forms complexes with 68Ga3+ rapidly at a low concentration, at room temperature, and over a wide pH range, enabling direct elution from a 68Ge/68Ga generator into a lyophilized radiopharmaceutical kit in 1 step without manipulation. The aim of this phase 1 study was to assess the safety and biodistribution of 68Ga-THP-PSMA. Methods: Cohort A comprised 8 patients who had proven prostate cancer and were scheduled to undergo prostatectomy; they had Gleason scores of 7-10 and a mean prostate-specific antigen level of 7.8 μg/L (range, 5.4-10.6 μg/L). They underwent PET/CT after the administration of 68Ga-THP-PSMA. All patients proceeded to prostatectomy (7 with pelvic nodal dissection). Dosimetry from multi-time-point PET imaging was performed with OLINDA/EXM. Cohort B comprised 6 patients who had positive 68Ga-HBED-PSMA-11 PET/CT scanning results and underwent comparative 68Ga-THP-PSMA scanning. All patients were monitored for adverse events. Results: No adverse events occurred. In cohort A, 6 of 8 patients had focal uptake in the prostate (at 2 h: average SUVmax, 5.1; range, 2.4-9.2) and correlative 3+ staining of prostatectomy specimens on PSMA immunohistochemistry. The 2 68Ga-THP-PSMA scans with negative results had only 1+/2+ staining. The mean effective dose was 2.07E-02 mSv/MBq. In cohort B, 68Ga-THP-PSMA had lower physiologic background uptake than 68Ga-HBED-PSMA-11 (in the parotid glands, the mean SUVmax for 68Ga-THP-PSMA was 3.6 [compared with 19.2 for 68Ga-HBED-PSMA-11]; the respective corresponding values in the liver were 2.7 and 6.3, and those in the spleen were 2.7 and 10.5; P < 0.001 for all). In 5 of 6 patients, there was concordance in the number of metastases identified with 68Ga-HBED-PSMA-11 and 68Ga-THP-PSMA. Thirteen of 15 nodal abnormalities were subcentimeter. In 22 malignant lesions, the tumor-to-liver contrast with 68Ga-THP-PSMA was similar to that with 68Ga-HBED-PSMA (4.7 and 5.4, respectively; P = 0.15), despite a higher SUVmax for 68Ga-HBED-PSMA than for 68Ga-THP-PSMA (30.3 and 10.7, respectively; P < 0.01). Conclusion:68Ga-THP-PSMA is safe and has a favorable biodistribution for clinical imaging. Observed focal uptake in the prostate was localized to PSMA-expressing malignant tissue on histopathology. Metastatic PSMA-avid foci were also visualized with 68Ga-THP-PSMA PET. Single-step production from a Good Manufacturing Practice cold kit may enable rapid adoption.
引用
- Hofman MS, Eu P, Jackson P, et al. Cold Kit for Prostate-Specific Membrane Antigen (PSMA) PET Imaging: Phase 1 Study of 68Ga-Tris(Hydroxypyridinone)-PSMA PET/CT in Patients with Prostate Cancer. J Nucl Med. 2017. PMID: 28986512. doi:10.2967/jnumed.117.199554
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。